11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genome‐wide cooperation of EMT transcription factor ZEB1 with YAP and AP‐1 in breast cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Invasion, metastasis and therapy resistance are the major cause of cancer‐associated deaths, and the EMT‐inducing transcription factor ZEB1 is a crucial stimulator of these processes. While work on ZEB1 has mainly focused on its role as a transcriptional repressor, it can also act as a transcriptional activator. To further understand these two modes of action, we performed a genome‐wide ZEB1 binding study in triple‐negative breast cancer cells. We identified ZEB1 as a novel interactor of the AP‐1 factors FOSL1 and JUN and show that, together with the Hippo pathway effector YAP, they form a transactivation complex, predominantly activating tumour‐promoting genes, thereby synergising with its function as a repressor of epithelial genes. High expression of ZEB1, YAP, FOSL1 and JUN marks the aggressive claudin‐low subtype of breast cancer, indicating the translational relevance of our findings. Thus, our results link critical tumour‐promoting transcription factors: ZEB1, AP‐1 and Hippo pathway factors. Disturbing their molecular interaction may provide a promising treatment option for aggressive cancer types.

          Abstract

          Aggressive cellular states in human breast cancer are defined by context‐dependent interplay between transcriptional regulators ZEB1, AP‐1 and YAP.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: not found
          • Article: not found

          AP-1: a double-edged sword in tumorigenesis.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression

            One of the most common analysis tasks in genomic research is to identify genes that are differentially expressed (DE) between experimental conditions. Empirical Bayes (EB) statistical tests using moderated genewise variances have been very effective for this purpose, especially when the number of biological replicate samples is small. The EB procedures can however be heavily influenced by a small number of genes with very large or very small variances. This article improves the differential expression tests by robustifying the hyperparameter estimation procedure. The robust procedure has the effect of decreasing the informativeness of the prior distribution for outlier genes while increasing its informativeness for other genes. This effect has the double benefit of reducing the chance that hypervariable genes will be spuriously identified as DE while increasing statistical power for the main body of genes. The robust EB algorithm is fast and numerically stable. The procedure allows exact small-sample null distributions for the test statistics and reduces exactly to the original EB procedure when no outlier genes are present. Simulations show that the robustified tests have similar performance to the original tests in the absence of outlier genes but have greater power and robustness when outliers are present. The article includes case studies for which the robust method correctly identifies and downweights genes associated with hidden covariates and detects more genes likely to be scientifically relevant to the experimental conditions. The new procedure is implemented in the limma software package freely available from the Bioconductor repository.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance.

              Zinc finger E-box binding homeobox 1 (ZEB1) is a transcription factor that promotes tumor invasion and metastasis by inducing epithelial-mesenchymal transition (EMT) in carcinoma cells. EMT not only plays an important role in embryonic development and malignant progression, but is also implicated in cancer therapy resistance. It has been hypothesized that carcinoma cells that have undergone EMT acquire cancer stem cell properties including self-renewal, chemoresistance and radioresistance. However, our recent data indicate that ZEB1 regulates radioresistance in breast cancer cells through an EMT-independent mechanism. In this Perspective, we review different mechanisms by which ZEB1 regulates tumor progression and treatment resistance. Based on studies by us and others, we propose that it is specific EMT inducers like ZEB1, but not the epithelial or mesenchymal state itself, that dictate cancer stem cell properties.
                Bookmark

                Author and article information

                Contributors
                thomas.brabletz@fau.de
                simone.brabletz@fau.de
                Journal
                EMBO J
                EMBO J
                10.1002/(ISSN)1460-2075
                EMBJ
                embojnl
                The EMBO Journal
                John Wiley and Sons Inc. (Hoboken )
                0261-4189
                1460-2075
                21 July 2020
                01 September 2020
                21 July 2020
                : 39
                : 17 ( doiID: 10.1002/embj.v39.17 )
                : e103209
                Affiliations
                [ 1 ] Department of Experimental Medicine 1 Nikolaus‐Fiebiger‐Center for Molecular Medicine Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany
                [ 2 ] Institute of Human Genetics Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany
                [ 3 ] Department of Nephropathology Institute of Pathology Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany
                [ 4 ] Institute of Pathology Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany
                [ 5 ] Department of Visceral Surgery Faculty of Biology University of Freiburg Freiburg Germany
                [ 6 ] Regensburg Center for Interventional Immunology (RCI) University Regensburg and University Medical Center Regensburg Germany
                [ 7 ] Max Planck Institute of Immunobiology and Epigenetics Freiburg Germany
                [ 8 ] Comprehensive Cancer Center Erlangen‐EMN Erlangen University Hospital Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany
                [ 9 ]Present address: Institute of Molecular Oncology and Functional Genomics TUM School of Medicine Technical University Munich Germany
                [ 10 ]Present address: Charité – Universitätsmedizin Berlin Digital Health Center Berlin Germany
                Author notes
                [*] [* ] Corresponding author. Tel: +49 9131 8529104; E‐mail: thomas.brabletz@ 123456fau.de

                Corresponding author. Tel: +49 9131 8529101; E‐mail: simone.brabletz@ 123456fau.de

                [†]

                These authors contributed equally to this work

                [‡]

                These authors jointly supervised this work

                Author information
                https://orcid.org/0000-0003-4011-4638
                https://orcid.org/0000-0002-4566-2986
                https://orcid.org/0000-0001-7045-6327
                https://orcid.org/0000-0002-7866-3686
                https://orcid.org/0000-0003-2983-9048
                https://orcid.org/0000-0003-0936-1526
                Article
                EMBJ2019103209
                10.15252/embj.2019103209
                7459422
                32692442
                7c6b61bd-d120-42b3-a6ea-8d689c84e87b
                © 2020 The Authors. Published under the terms of the CC BY NC ND 4.0 license

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 13 August 2019
                : 17 June 2020
                : 18 June 2020
                Page count
                Figures: 13, Tables: 0, Pages: 21, Words: 16178
                Funding
                Funded by: Deutsche Forschungsgemeinschaft (DFG) , open-funder-registry 10.13039/501100001659;
                Award ID: SFB992/C06
                Award ID: BR 1399/9‐1
                Award ID: BR 1399/10‐1
                Award ID: BR 1399/13‐1
                Award ID: BR 4145/1‐1
                Award ID: BR 4145/2‐1
                Funded by: Interdisziplin‐äres Zentrum für Klinische Forschung, Universitätsklinikum Erlangen
                Award ID: F4‐46
                Funded by: Universität Erlangen, Medizinische Fakultät, ELAN
                Award ID: 29624020
                Categories
                Article
                Articles
                Custom metadata
                2.0
                01 September 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.8 mode:remove_FC converted:01.09.2020

                Molecular biology
                ap‐1,breast cancer,epithelial to mesenchymal transition,zeb1,cancer,chromatin, epigenetics, genomics & functional genomics

                Comments

                Comment on this article